ABSTRACT
The search for a potent anti-coronavirus therapy for severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) remains an overwhelming task since the outbreak of COVID-19. It is more evident that most of the existing antiviral and immune-boosting drugs are non-promising and ineffective for the treatment of coronavirus infected patients while the safety of a few drugs/vaccines that have demonstrated high potential remains unclear. With daily records of confirmed infectious cases across the world, it is crucial to emphasize the need for repurposed therapies with a validated ethnomedicinal base focused on well-known active medicines with traceable biochemical, pharmacological and safety profiles for viral infection management. In the present study, recent literature on Artemisia and Artemisia-based products for the management of COVID-19 are reviewed. Artemisia-based products have demonstrated a broad spectrum of biological ability including antiviral properties. Besides its antiviral activity, Artemisia annua have shown to contain appreciable amounts of minerals such as zinc, gallium and selenium among others. Graphic abstract: [Figure not available: see fulltext.].Copyright © 2021, Institute of Korean Medicine, Kyung Hee University.
ABSTRACT
Introduction: The World Health Organization (WHO) has recently declared the outbreak and spread of the new strain of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS--CoV-2) a global pandemic. In this regard, a lot of scientific investigations and clinical trials on some existing antiviral and antibiotic drugs have been ongoing to combat this menace. Method(s): In the past, conventional drug therapy has shown irregular drug distribution, poor solubil-ity, and low permeability to target cells, organs, and tissues. However, Chloroquine, Hydrox-ychloroquine Remdesivir, Lopinavir/Ritonavir, etc. have attracted several investigations in mono-therapeutic approaches and a combination of therapy have shown promising effects in reducing viral loading in some SARS-CoV-2 infected patients. Nevertheless, the advent of nanomedicine has triggered serious attention on drug-loaded nanoparticle as nanocarriers to deliver bioactive drug molecules to target organs with increased circulation and controlled release. Therefore, the application of nanoparticles as nanocarriers for the controlled release of antiviral drugs would improve the ease of drug administration and care of patients admitted at various health care facilities world-wide. Conclusion(s): Owing to their small sizes, biocompatibility, and high encapsulation properties, nano-particles can be utilized as potential nanocarrier of antiviral drugs for the SARS-CoV-2 management at a reduced cost with minimal side effect in the body system. In addition, some noticeable concerns on the ongoing management of SARS-CoV-2 pandemic in developing nations have been presented for concerted attention.Copyright © 2021 Bentham Science Publishers.